Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma
Open Access
- 17 May 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 106 (12), 1997-2003
- https://doi.org/10.1038/bjc.2012.145
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Activation of c-Jun N-terminal kinase in non-cancerous liver tissue predicts a high risk of recurrence after hepatic resection for hepatocellular carcinomaHepatology Research, 2012
- Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulationJCI Insight, 2008
- MAP kinase signalling pathways in cancerOncogene, 2007
- p38α suppresses normal and cancer cell proliferation by antagonizing the JNK–c-Jun pathwayNature Genetics, 2007
- Cancer Stem CellsThe New England Journal of Medicine, 2006
- Phase II Study of Sorafenib in Patients With Advanced Hepatocellular CarcinomaJournal of Clinical Oncology, 2006
- Ubiquitous Activation of Ras and Jak/Stat Pathways in Human HCCGastroenterology, 2006
- Tumour stem cells and drug resistanceNature Reviews Cancer, 2005
- Liver Tumor Development: c-Jun Antagonizes the Proapoptotic Activity of p53Cell, 2003
- Mammalian MAP kinase signalling cascadesNature, 2001